Professor Howard Gurney is the Director of Medical Oncology and Clinical Trials at Macquarie University and Director of Clinical Research in Medical Oncology at Westmead Hospital. Dr Gurney has a firm background in clinical research and has subspecialty interests in uro-genital cancers including prostate, bladder, testis and kidney cancer. He has been principle investigator for over 100 clinical trials and has published over 90 peer-reviewed articles in journals and book chapters. Current research interests include the pharmacogenomics and therapeutic monitoring of chemotherapy and targeted therapies and he has published widely in this area. He is regarded as a leading authority on mechanisms for safe dosing of anticancer agents and has written a number of invited editorials on this topic for Lancet Oncology and the Journal of Clinical Oncology.
Abstracts this author is presenting: